BOCA RATON, Fla., Feb. 11 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG, Dreieich, Germany, announced that it has acquired a plasma collection facility located at 2860 Cerrillos Road, Santa Fe, New Mexico from Talecris Plasma Resources, Inc. With this acquisition, BPC now operates 11 plasma centers in various locations throughout the United States. Last year, the company announced it had aggressive plans for further expansion during the next two years. BPC will continue to explore opportunities to expand its plasma collection operations to address the global demand for this very important source material. Financial terms of the purchase were not disclosed.
"We are extremely pleased to add the Santa Fe facility to our network of plasma centers in the U.S.," remarked Dr. Rainer Pabst, Chief Executive Officer of BPC. "We are looking forward to continuing to build upon our existing foundation to reach our goals of continued growth and expanded range of top-quality plasma products."
About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation develops and manufactures pharmaceutical and biotherapeutic products with a specialization in immunology. Biotest Pharmaceuticals was formed in 2007 as part of the Biotest AG acquisition of Nabi Pharmaceuticals' Biologics business unit, including its plasmapheresis centers across the United States. The company employs approximately 560 people in the U.S. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins that employs approximately 1,850 people worldwide.
To learn more about Biotest Pharmaceuticals and how we help make a difference in the lives of patients and the healthcare community, please visit us at www.biotestpharma.com
About Biotest AG
Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialized in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and immunological diagnostics which are used, for example, in blood transfusions and transplants. Biotest has around 1,950 employees worldwide and its shares are listed in the Stock Exchange's SDAX on the Frankfurt Stock Exchange.
|SOURCE Biotest Pharmaceuticals Corporation|
Copyright©2009 PR Newswire.
All rights reserved